Clinical Trials

91 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01004640 2023-09-14

Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial

60 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04155411 2022-07-27

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05154474 2022-05-03

SPACE2

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

150 enrolled

Anemia, Refractory, with Excess of Blasts, Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Sarcopenia

NCT02602314 2022-01-20

SUSTRENIM

450 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01752062 2022-01-05

CML1012

148 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01761890 2022-01-05

CML1113

147 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05092048 2021-10-25

Case-Only

10,000 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05080829 2021-10-18

Myeloid Mutations Register in R/R CML

Phase NA Unknown

29 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04991532 2021-08-05

Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

324 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04818619 2021-03-29

TIGIT in Patients With Chronic Myeloid Leukemia

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04709731 2021-02-03

CarPAs

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02172365 2020-11-02

Allogeneic SCT for CML, TKI Failure After TKI Failure

350 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01046305 2020-01-07

Symptom Burden in Chronic Myeloid Leukemia (CML)

210 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02268370 2019-11-29

TRAD

131 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04150471 2019-11-04

Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients

79 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03907670 2019-09-30

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

45 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04104035 2019-09-27

Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04043676 2019-08-02

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

40 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03075969 2019-03-21

Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

337 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03348033 2019-03-12

Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia

Phase 1/2 Unknown

5 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03625583 2018-08-10

The Hong Kong CML Registry

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02164903 2018-08-06

QoL-CML0713

323 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03515018 2018-05-22

HU

Phase 3 Unknown

60 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02889003 2018-03-22

PIO2STOP

26 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03353558 2017-11-28

CML-SLEEP

Sleep Wake Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02869256 2017-11-21

LMC

400 enrolled

Phase EARLY_PHASE1 Unknown

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03228303 2017-10-10

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03241199 2017-08-08

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

15 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03216070 2017-07-13

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

12 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03205267 2017-07-02

BODO

127 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02975115 2016-11-29

Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization

102 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02903277 2016-09-16

National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent

150 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02883036 2016-08-30

Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01690065 2016-05-11

NICE-BORA

46 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02422719 2016-05-11

REVITAL

73 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02687425 2016-02-22

SESPI

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01802450 2015-09-17

DASAPOST

18 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389920 2015-03-17

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

40 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02007811 2014-03-26

B-cell therapy

Phase 1/2 Unknown

15 enrolled

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01400074 2014-01-13

RE-NICE

Phase 3 Unknown

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01562847 2014-01-13

AMICAN

125 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01564836 2014-01-13

Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Phase NA Unknown

50 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02034656 2014-01-13

Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)

125 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01221376 2013-03-26

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01627132 2012-06-25

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

50 enrolled